Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9025467 | 0.89 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL2077398 | 0.85 | — | — | |
| SCHEMBL9387059 | 0.81 | ALDH1A1 (0.32) | PIK3CD | |
| SCHEMBL272355 | 0.78 | — | — | |
| SCHEMBL1292539 | 0.72 | PIK3CD (0.43) | PIK3CDCTH | |
| SCHEMBL2075859 | 0.71 | — | — | |
| SCHEMBL11793063 | 0.69 | PIK3CD (0.42) | PIK3CDCTH | |
| SCHEMBL15745725 | 0.69 | PIK3CD (0.42) | PIK3CDCTH | |
| SCHEMBL174185 | 0.69 | — | — | |
| SCHEMBL259497 | 0.69 | PIK3CD (0.62) | PIK3CDCTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012048411-A1 | PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2012-04-19 | — | — | WO | claimed |
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | claimed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | claimed |
| US-9724333-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160228412-A1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECH CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9321752-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-04-26 | — | — | US | disclosed |
| US-20150252029-A1 | Novel Pyrazole Derivative | GREEN TECH CO., LTD. (JP) | 2015-09-10 | — | — | US | disclosed |
| EP-2907805-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2015-08-19 | — | — | EP | disclosed |
| WO-2012048411-A1 | PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2012-04-19 | — | — | WO | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| EP-0501693-B1 | Isoquinoline derivatives | BANYU PHARMA CO LTD (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5362736-A | Alkoxy derivatives for cardiovascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-11-08 | — | — | US | disclosed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
| EP-0501693-A1 | Isoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4065560-A | Tetrahydro-2-(nitromethylene)-2H-1,3-thiazine insect control agents | SHELL OIL COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-3993648-A | Tetrahydro-2-(nitromethylene)-2H-1,3-thiazines | SHELL OIL COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228412-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, PSEN1, MAPT | PIK3CD 2746/4885CTH 3629/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | PIK3CD 4035/4885CTH 3030/4885 |
| US-20150252029-A1 | Novel Pyrazole Derivative | PSEN2, PSEN1, MAPT | PIK3CD 2746/4885CTH 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.